

## Curriculum Vitae – Prof. Dr. med. Nisar Peter Malek

### Personal Data

Title	Prof. Dr. med.
First name	Nisar Peter
Name	Malek
Current position	Full Professor (W3, permanent); Chair/Director, Dept. of Internal Medicine I (Gastroenterology, Hepatology, Infectiology, GI Oncology, Geriatrics)
Current institution(s)/site(s), country	University Hospital and Faculty of Medicine Tübingen, Tübingen, Germany
Identifiers/ORCID	ORCID: n/a; Wikipedia: <a href="https://de.wikipedia.org/wiki/Nisar_Peter_Malek">https://de.wikipedia.org/wiki/Nisar_Peter_Malek</a>

### Qualifications and Career

Stages	Periods and Details	
Degree program	<b>1989-1996</b>	Medicine, Hannover Medical School (MHH) (as stated in summary)
Doctorate	<b>03/1996</b>	Doctor of Medicine (Dr. med.), Hannover Medical School (MHH). Doctoral thesis 10/1991-09/1993, Institute of Molecular Biology, MHH (Prof. Alfred Nordheim).
Stages of academic/professional career	<b>1998 - 2001</b>	Postdoctoral Fellow (DFG training grant), Fred Hutchinson Cancer Research Center, Seattle, WA, USA (Prof. James M. Roberts).
	<b>02/2001</b>	Scientific assistant, Dept. of Gastroenterology, Hepatology and Endocrinology, MHH (Prof. M. P. Manns) and Group leader, Institute of Molecular Biology, MHH (Prof. Achim Gossler).
	<b>10/2002</b>	Head of working group, Max Eder Program, German Cancer Aid (Phase 1: 2002-2005; Phase 2: 2005-2008)
	<b>01/2004</b>	Project leader, DFG Clinical Research Unit 119: “Molecular basis and consecutive therapeutic approaches in hepatocellular carcinoma”
	<b>04/2006</b>	Specialist in Internal Medicine
	<b>10/2006</b>	Senior physician, Dept. of Gastroenterology, Hepatology and Endocrinology, MHH
	<b>05/2007</b>	Venia legendi (Internal Medicine), Hannover Medical School
	<b>01/2007</b>	Head, working group “Cell Proliferation Control”, DFG Cluster of Excellence REBIRTH
	<b>01/2007</b>	Head, TransMedLab, Helmholtz Centre for Infection Research, Braunschweig
	<b>05/2007</b>	Project leader, SFB 738 “Optimization of conventional and innovative transplants”
	<b>11/2007</b>	Spokesman, AG Drug Development Phase I/II Studies, Association of Internal Oncology (AIO)

	<b>02/2008</b>	Professor (W2) "Cell Proliferation Control", DFG Cluster of Excellence REBIRTH, MHH
	<b>01/2009</b>	Additional qualification in Gastroenterology
	<b>01/2010</b>	Project leader, TR77 "Liver Cancer from Molecular Pathogenesis to Targeted Therapies"
	<b>since 09/2011</b>	Full Professor and Director/Chair, Internal Medicine I (Gastroenterology, Hepatology, Infectiology), University Hospital Tübingen
	<b>since 04/2012</b>	Member, Executive Board, Department of Internal Medicine, University Hospital Tübingen
	<b>08/2013</b>	Deputy Director, Comprehensive Cancer Center (CCC) Tübingen
	<b>Since 01/2015</b>	Chairman of the Board, Center for Personalized Medicine (ZPM) Tübingen; Platform 1, Excellence Initiative, University of Tübingen
	<b>Since 01/2015</b>	Spokesman, ZPM Network Baden-Württemberg.
	<b>Since 10/2015</b>	Managing Director, Department of Internal Medicine, University Hospital Tübingen
	<b>Since 01/2017</b>	Founding Director, M3 Research Institute, University Hospital Tübingen
	<b>01/2017-2022</b>	Co-Speaker, DFG Collaborative Research Center Liver Cancer
	<b>Since 01/2019</b>	Spokesperson, ZPM network in the state advisory board "Personalized Medicine"
	<b>Since 01/2021</b>	Consortium leader, German Network Personalized Medicine (DNPM)

## Activities in the Research System

### *Committees and (inter)national boards (selection)*

Since 2012 Member, Scientific Advisory Board, Comprehensive Cancer Center Göttingen.

Since 2012 Member, Advisory Board, Cancer Center Toulouse.

Since 2012 Member, Board of Trustees, Fritz Lipmann Institute for Ageing Research, Jena.

2014-2024 Member, Expert Committee "Medical and Scientific Promotion of Young Researchers", German Cancer Aid.

Since 2015 Chairman, Commission "Science and Promotion of Young Researchers", German Society for Internal Medicine (DGIM).

Since 01/2021 Member, Steering Committee "genom.de", Federal Ministry of Health.

Since 01/2022 Spokesperson, interministerial working group Baden-Württemberg "Standardization of data and data access".

Since 01/2022 Commission spokesperson, German Cancer Society (DKG) Certification Commission for Centers for Personalized Medicine.

## Supervision of Researchers in Early Career Phases

### • *Supervision of Postdoctoral Researchers and Clinician Scientists*

Supervision of 6 Postdoctoral researchers (2 female, 4 male), 6 Clinician Scientists (3 female, 3 male)

### • *Supervision of PhD students*

>10 PhD students completed

- *Supervision of Medical Students*  
>10 MD thesis completed
- *Supervision of Master students and Bachelor Students*  
5 Master thesis completed

## Scientific Results

### Category A

\* First author, \*\* senior author, [OA]: open access

1. \*\* Illert AL, Stenzinger A, Bitzer M, [...], **Malek NP**. "The German Network for Personalized Medicine to Enhance Patient Care and Translational Research". **Nature Medicine**, 2023; 29(6):1298-1301. doi:10.1038/s41591-023-02354-z
2. \*\* Bitzer M, Spahn S, Babaei S, [...], **Malek NP**. "Targeting Extracellular and Juxtamembrane FGFR2 Mutations in Chemotherapy-Refractory Cholangiocarcinoma". **NPJ Precision Oncology**, 2021; 5:80. doi:10.1038/s41698-021-00220-0
3. \*\* Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, **Malek NP**. "Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options". **JCO Precision Oncology**, 2020; 4. doi:10.1200/PO.19.00359
4. \*\* Zender S, Nিকেleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, **Malek NP**. "A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas". **Cancer Cell**, 2013; 23(6):784-795. doi:10.1016/j.ccr.2013.04.019
5. \*\* Puklowski A, Homsy Y, Keller D, May M, Chauhan S, Kossatz U, Grünwald V, Kubicka S, Pich A, Manns MP, Hoffmann I, Gönczy P, **Malek NP**. "The SCF-FBXW5 E3-Ubiquitin Ligase Is Regulated by PLK4 and Targets HsSAS-6 to Control Centrosome Duplication". **Nature Cell Biology**, 2011; 13(8):1004-1009. doi:10.1038/ncb2282.
6. \*\* Nিকেleit I, Zender S, Sasse F, Geffers R, Brandes G, Sörensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gütgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, **Malek NP**. "Argyris A Reveals a Critical Role for the Tumor Suppressor Protein p27(Kip1) in Mediating Antitumor Activities in Response to Proteasome Inhibition". **Cancer Cell**, 2008; 14(1):23-35. doi:10.1016/j.ccr.2008.05.016
7. \*\* Timmerbeul I, Garrett-Engle CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, Manns MP, Porter PL, Roberts JM, **Malek NP**. "Testing the Importance of p27 Degradation by the SCF-SKP2 Pathway in Murine Models of Lung and Colon Cancer". **Proc Natl Acad Sci U S A**, 2006;103(38):14009-14014. doi:10.1073/pnas.0606316103
8. \*\* Kossatz U, Vervoorts J, Nিকেleit I, Sundberg HA, Arthur JS, Manns MP, **Malek NP**. "C-Terminal Phosphorylation Controls the Stability and Function of p27Kip1". **EMBO Journal**, 2006; 25(21):5159-5170. doi:10.1038/sj.emboj.7601388
9. \*\* Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, **Malek NP**. "Skp2-Dependent Degradation of p27kip1 Is Essential for Cell Cycle Progression". **Genes & Development**, 2004; 18(21):2602-2607. doi:10.1101/gad.321004.

10. \* **Malek NP**, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM. "A Mouse Knock-in Model Exposes Sequential Proteolytic Pathways That Regulate p27Kip1 in G1 and S Phase".  
**Nature**, 2001; 413(6853):323-327. doi:10.1038/35095083.

### **Ongoing Patent Applications**

- ARGYRIN-GB (ARG-PCT-1), **US8217071B2 / EP2120929B1 / WO2010006682A1**
- PROTEASOME-GB (PROT-INT-1), **US9458200B2**
- CELL-GROWTH-GB (GROWTH-US-1), **US7435591B2**

### **Prizes and Awards**

2008 Science Prize of the Association of Internal Oncology (AIO).

2009 Johann-Georg-Zimmermann Prize for Cancer Research (donated by Deutsche Hypothekenbank)

### **Memberships**

German Society for Internal Medicine (DGIM).

German Society for Digestive and Metabolic Diseases (DGVS).

German Cancer Society (DKG).

Working Group for Internal Oncology (AIO).